Characterization of the Immune Response in Patients with Cancer of the Oral Cavity After Neoadjuvant Immunotherapy with the IRX-2 Regimen

Overview

Journal Oral Oncol

Publisher Elsevier

Specialty Dentistry

Date 2021 Oct 30

PMID 34717154

Citations 2

Authors

Siyu Liu

Emily Bellile

Ariane Nguyen

Katie Zarins

Nisha DSilva

Laura Rozek

Gregory T Wolf

Maureen A Sartor

Affiliations

Soon will be listed here.

Abstract

Objective: IRX-2 is a homologous cell-derived multi-cytokine biologic with multifaceted immune modulatory effects that has been shown to induce increased lymphocyte infiltration into primary tumors in oral cavity carcinoma. Our objective was to characterize tumor immune gene expression and epigenomic changes after neoadjuvant IRX-2 immunotherapy in patients with squamous cell carcinoma of the oral cavity.

Methods: A randomized phase II trial was conducted of the IRX regimen 3 weeks prior to surgery for previously untreated patients with Stage II-IV oral cavity carcinoma. The treatment regimen consisted of low dose (300 mg/m) cyclophosphamide (day 1) followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc and omeprazole (Regimen 1) compared to the identical regimen without the IRX-2 cytokines (Regimen 2). The NanoString immune panel (730 genes) and Infinium MethylationEPIC BeadChip were performed to assess the gene expression and DNA methylation signatures, respectively, in pre- and post-immunotherapy tumor samples.

Results: A total of 51 and 79 immune-related genes were found upregulated and downregulated, respectively, in the samples from Regimen 1 patients after treatment, while 51 and 56 were found upregulated and downregulated in the samples for Regimen 2. When comparing the changes between the two regimens, we identified 9 genes significantly different, including DMBT1, a potential tumor suppressor, functioning in tumor invasion of head and neck cancer. The exploration of DNA methylation showed slight overall hypermethylation after treatment in both regimens, especially for Regimen 1 immune responders, and methylation-based cell type deconvolution demonstrated high concordance with tumor infiltrating T lymphocyte cell counts.

Conclusion: While a consistent patient response after treatment was observed, most changes were similar between regimens, indicating a subtle, targeted, or patient-specific effect of IRX-2 cytokines. Change in DMBT1 expression was a unique finding that will require further study to better understand its significance.

Citing Articles

Stachydrine targeting tumor-associated macrophages inhibit colorectal cancer liver metastasis by regulating the JAK2/STAT3 pathway.

Gui Y, Xue G, Yuan Y, Wang J, Deng S, Gao F Front Pharmacol. 2025; 16:1514158.

PMID: 39974738 PMC: 11835834. DOI: 10.3389/fphar.2025.1514158.

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics.

Dwivedi R, Jain A, Gupta S, Chandra S Indian J Otolaryngol Head Neck Surg. 2024; 76(3):2257-2272.

PMID: 38883453 PMC: 11169205. DOI: 10.1007/s12070-024-04565-3.

The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas.

Kondoh N, Mizuno-Kamiya M Cancers (Basel). 2022; 14(12).

PMID: 35740551 PMC: 9221278. DOI: 10.3390/cancers14122884.

References

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

Tuttolomondo M, Casella C, Lund Hansen P, Polo E, Herda L, Dawson K . Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery. Mol Ther Nucleic Acids. 2017; 8:264-276. PMC: 5514624. DOI: 10.1016/j.omtn.2017.06.020. View

Xue G, Cui Z, Zhou X, Zhu Y, Chen Y, Liang F . DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. Front Genet. 2019; 10:724. PMC: 6707807. DOI: 10.3389/fgene.2019.00724. View

Goltz D, Gevensleben H, Dietrich J, Schroeck F, de Vos L, Droege F . PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget. 2017; 8(25):41011-41020. PMC: 5522222. DOI: 10.18632/oncotarget.17354. View

Bais M . Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma. J Dent Res. 2019; 98(3):268-276. PMC: 6385352. DOI: 10.1177/0022034518816947. View

Smith I, Mydlarz W, Mithani S, Califano J . DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer. 2007; 121(8):1724-8. DOI: 10.1002/ijc.22889. View

Canning M, Guo G, Yu M, Myint C, Groves M, Byrd J . Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Front Cell Dev Biol. 2019; 7:52. PMC: 6465325. DOI: 10.3389/fcell.2019.00052. View

Chakravarthy A, Furness A, Joshi K, Ghorani E, Ford K, Ward M . Pan-cancer deconvolution of tumour composition using DNA methylation. Nat Commun. 2018; 9(1):3220. PMC: 6089972. DOI: 10.1038/s41467-018-05570-1. View

10.

Argiris A, Karamouzis M, Raben D, Ferris R . Head and neck cancer. Lancet. 2008; 371(9625):1695-709. PMC: 7720415. DOI: 10.1016/S0140-6736(08)60728-X. View

11.

Jung H, Kim H, Kim J, Sun J, Ahn J, Ahn M . DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. Nat Commun. 2019; 10(1):4278. PMC: 6753140. DOI: 10.1038/s41467-019-12159-9. View

12.

Misawa K, Yamada S, Mima M, Nakagawa T, Kurokawa T, Imai A . Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer. Biomark Res. 2020; 8:53. PMC: 7585304. DOI: 10.1186/s40364-020-00235-y. View

13.

Fortin J, Labbe A, Lemire M, Zanke B, Hudson T, Fertig E . Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 2015; 15(12):503. PMC: 4283580. DOI: 10.1186/s13059-014-0503-2. View

14.

Wolfer S, Elstner S, Schultze-Mosgau S . Degree of Keratinization Is an Independent Prognostic Factor in Oral Squamous Cell Carcinoma. J Oral Maxillofac Surg. 2017; 76(2):444-454. DOI: 10.1016/j.joms.2017.06.034. View

15.

Ahlmann M, Hempel G . The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016; 78(4):661-71. DOI: 10.1007/s00280-016-3152-1. View

16.

Castilho R, Squarize C, Almeida L . Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int J Mol Sci. 2017; 18(7). PMC: 5535996. DOI: 10.3390/ijms18071506. View

17.

End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S . DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands. Eur J Immunol. 2009; 39(3):833-42. DOI: 10.1002/eji.200838689. View

18.

Piao S, Inglehart R, Scanlon C, Russo N, Banerjee R, DSilva N . CDH11 inhibits proliferation and invasion in head and neck cancer. J Oral Pathol Med. 2016; 46(2):89-97. DOI: 10.1111/jop.12471. View

19.

Singh P, Banerjee R, Piao S, Medeiros M, Bellile E, Liu M . Squamous cell carcinoma subverts adjacent histologically normal epithelium to promote lateral invasion. J Exp Med. 2021; 218(6). PMC: 8042603. DOI: 10.1084/jem.20200944. View

20.

Peters T, Buckley M, Statham A, Pidsley R, Samaras K, Lord R . De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin. 2015; 8:6. PMC: 4429355. DOI: 10.1186/1756-8935-8-6. View